About GeneIII
GeneIII is a company based in Nanjing (China) founded in 2021. GeneIII has raised $13.76 million across 1 funding round from investors including JAFCO Asia. GeneIII offers products and services including Ergothioneine (EGT) and Skincare and Supplement Applications.
- Headquarter Nanjing, China
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name 江苏仅三生物科技有限公司
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$13.76 M (USD)
in 1 rounds
-
Latest Funding Round
$13.76 M (USD), Seed
Apr 03, 2025
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GeneIII
GeneIII offers a comprehensive portfolio of products and services, including Ergothioneine (EGT) and Skincare and Supplement Applications.
Ergothioneine is produced as an antioxidant raw material for health and beauty applications
Applications of Ergothioneine are supplied for oral capsules and skincare formulations
Funding Insights of GeneIII
GeneIII has successfully raised a total of $13.76M through 1 strategic funding round. The most recent funding activity was a Seed round of $13.76 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $13.8M
-
First Round
First Round
(03 Apr 2025)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Seed - GeneIII | Valuation | JAFCO Asia |
|
Investors in GeneIII
GeneIII has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include JAFCO Asia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in early-stage tech startups are made by JAFCO Asia.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GeneIII
Financial Statements - GeneIII
Geneiii Comparisons
Competitors of GeneIII
Latest news on Geneiii
Frequently Asked Questions about GeneIII
GeneIII was founded in 2021 and raised its 1st funding round 4 years after it was founded.
GeneIII is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
GeneIII is a funded company, having raised a total of $13.76M across 1 funding round to date. The company's 1st funding round was a Seed of $13.76M, raised on Apr 03, 2025.
GeneIII was established in 2021 and is located in Nanjing, China. The company operates within the biotechnology sector, as indicated by its name and domain geneiii.com.cn. Operations are based in China, with a focus on genetic-related activities inferred from the branding. Specific services and detailed business scope are not outlined in available data, positioning it as an emerging entity in the regional biotech landscape.
GeneIII offers Ergothioneine (EGT) and Skincare and Supplement Applications.
GeneIII has 1 investor. Key investors include JAFCO Asia.